EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer

Yubin Chen, Qian Yan, Shiye Ruan, Jinwei Cui, Zhenchong Li, Zhongyan Zhang, Jiayu Yang, Jike Fang, SiYang Liu, Shanzhou Huang, Baohua Hou, Chuanzhao Zhang

Cell Reports · 2025-06 · 44 (6) · 115774

DOI: 10.1016/j.celrep.2025.115774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025-06. Verfasst von Yubin Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou…. Hauptthemen laut MEDLINE: Ferroptosis, Proto-Oncogene Proteins p21(ras), Mutation, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS mutations drive tumorigenesis, but their role in ferroptosis regulation remains unclear. Here, we construct wild-type KRAS (KRASWT) and KRASG12D-mutant cancer cells and demonstrate that G12D-mutant cells exhibit increased viability and reduced ferroptosis upon RSL3 or erastin treatment. These cells show diminished lipid peroxidation and mitochondrial damage, indicating ferroptosis resistance. KRASG12D activates MEK/ERK signaling to phosphorylate LDHA, enhancing glycolysis and lactate production. Exogenous lactate supplementation similarly protects WT cells from ferroptosis. Mechanistically, G12D-mutation-derived lactate induces glutamate-cysteine ligase (GCL) modifier (GCLM) lactylation, a process catalyzed by acetyl-coenzyme A (CoA) acetyltransferase 2 (ACAT2). Inhibition of GCLM lactylation either through the mutation of the lactylation site or by knockdown of ACAT2 diminished the enzymatic activity of GCL and suppressed glutathione synthesis. Importantly, ACAT2 depletion overcomes ferroptosis resistance in KRASG12D-mutant tumors in vivo. Our findings reveal a KRASG12D-driven metabolic adaptation linking GCLM lactylation to ferroptosis resistance, proposing ACAT2 inhibition as a therapeutic strategy for KRAS-mutant cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisProto-Oncogene Proteins p21(ras)MutationNeoplasmsHumansAnimalsCell Line, TumorMiceMice, NudeGlutathionePiperazinesAmino Acid Transport System y+

Stichwörter der Autor:innen

CP: CancerCP: MetabolismGCLMKRAS mutationferroptosisglutamate-cysteine ligase modifierpancreatic cancerprotein lactylation

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanSLC7A11 protein, humanGlutathioneerastinPiperazinesAmino Acid Transport System y+

Autor:innen und Institutionen

  • Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; School of Medicine, South China University of Technolo…
  • Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
  • Junior Clinical Cooperation Unit Translational Gastrointestinal Oncology and Preclinical Models, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University,…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, Y., Yan, Q., Ruan, S., Cui, J., Li, Z., Zhang, Z., Yang, J., Fang, J., Liu, S., Huang, S., Hou, B., & Zhang, C. (2025). GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer. Cell Reports, 44(6), 115774. https://doi.org/10.1016/j.celrep.2025.115774

Vancouver

Chen Y, Yan Q, Ruan S, Cui J, Li Z, Zhang Z, et al. GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer. Cell Reports. 2025;44(6):115774. doi:10.1016/j.celrep.2025.115774

BibTeX
@article{Chen2025,
  author = {Chen, Yubin and Yan, Qian and Ruan, Shiye and Cui, Jinwei and Li, Zhenchong and Zhang, Zhongyan and Yang, Jiayu and Fang, Jike and Liu, SiYang and Huang, Shanzhou and Hou, Baohua and Zhang, Chuanzhao},
  title = {GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer},
  journal = {Cell Reports},
  year = {2025},
  volume = {44},
  number = {6},
  pages = {115774},
  doi = {10.1016/j.celrep.2025.115774}
}
Kostenlos starten →